miRNA EXPRESSION PROFILE ASSOCIATED WITH AGGRESSIVENESS OF BREAST CANCER OF DIFFERENT MOLECULAR SUBTYPES
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-2-2022-g.10453Keywords:
breast cancer, microRNA, molecular subtype, predicting a tumor processAbstract
Aim: to identify the expression profile of tumor-associated microRNAs and assess their clinical significance for predicting the breast cancer (BC) course of a particular molecular subtype. Object and methods: the study was conducted on clinical material of 151 patients with stage I–II BC aged 55.2 ± 4.1 years, who were hospitalized in the Kyiv City Clinical Oncology Center during 2013–2016. MicroRNA levels were determined using real-time reverse transcriptional polymerase chain reaction. Studies of the expression of steroid hormone receptors, HER2/neu and the proliferation marker Ki-67 in breast cancer cells were performed on paraffin sections of the operative material using the immunohistochemical method. Statistical processing of the obtained results was performed using the program GraphPad Prism, v.6.05 (GraphPad Software, Inc., San Diego, USA) taking into account the nature of the distribution of the obtained data. Results: It was found that high levels of expression of miRNA-10b, -126 and -221 and low miRNA-34a, -181a, -200b, -205 and -320a are characteristic of luminal A subtype of breast cancer; luminal B — high levels of miRNA-34a, -155, -200b, -205 and -320a and low levels of miRNA-10b, -126 and -221; HER2/neu-positive — high levels of miRNA-126 and -221 and low — mRNA-10b, -34a, -200b, -205 and -320a; basal — high levels of expression of miRNA-10b, -21 and -34a. The presence of correlations between the level of expression of tumor-associated microRNAs with the main clinical and pathological characteristics of patients with breast cancer of different molecular subtypes was determined. The relationship between the expression levels of the studied microRNAs and the rates of 3-year recurrence-free and 5-year overall survival in patients with breast cancer of different molecular subtypes was demonstrated. Conclusion: the possibility of using expression indicators of tumor-associated miRNAs to predict the aggressiveness of different molecular subtypes of breast cancer and assess the risk of recurrence is substantiated.
References
Chekhun VF. MicroRNAs are a key factor in the globalization of tumor-host relationships. Exp Oncol 2019; 41 (3): 188–94. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-3.13431.
Chekhun VF. MicroRNA in the tumor process. Oncology 2012; 15 (2): 136 (in Ukrainian)
Chekhun S, Bezdenezhnykh N, Shvets J, Lukianova N. Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Expl oncol 2013; 35 (3): 174–9.
Lukianova NY, Borіkun TV, Zadvornyi TV, et al. Diagnostic and prognostic value of tumor-associated miRNA-21, -125b and -221 in patients with the most common hormone-dependent malignancies. Oncology 2021; 23 (3): 123–9 (in Ukrainian)
Chekhun VF, Lukianova NY, Borikun TV, et al. The clinical significance of tumor miR-122, -155, -182, and -200b expression in patients with breast cancer. Science and Innovation 2017; 13 (5): 63–9 (in Ukrainian). doi: 10.32471/oncology.2663-7928.t-23-3-2021-g.9840
Nair MG, Somashekaraiah VM, Ramamurthy, et al. miRNAs: critical mediators of breast cancer metastatic programming. Exp Cell Res 2021; 401 (1): 112518. doi: 10.1016/j.yexcr.2021.112518.
Adhami M, Haghdoost AA, Sadeghi B, Afshar RM. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer 2018; 25 (2): 198–205. doi: 10.1007/s12282-017-0814-8
Healy N, Heneghan H, Muller N, et al. Systemic microRNA as potential biomarkers in cancer. Int J Cancer 2013; 131: 2265–71. doi:10.1002/ijc.27642
Tang Q, Ouyang H, He D, et al. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artif Cells Nanomed Biotechnol 2019; 47 (1): 2800–9. doi: 10.1080/21691401.2019.1638791
Sobin LH, Wittekind C. TNM. Classification of malignant tumors. Sixth Edition. UICC, Ed Willey-Liss 2003; 193.
Sobin LH, Gospodarowicz MK, Wittekind Ch, et al. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 7th edn. New York: Wiley, 2009
Lakhani S, Ellis I, Schnitt S, et al. 4th. WHO Classification of Tumours of the Breast. Lyon: IARC Press; 2012
Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986; 46 (10): 5419–25.
Zhang J, Yang J, Zhang X, et al. MicroRNA-10b expression in breast cancer and its clinical association. PLoS One 2018; 13 (2): e0192509. doi: 10.1371/journal.pone.0192509
Wang J, Yan Y, Zhang Z, Li Y. Role of miR-10b-5p in the prognosis of breast cancer. PeerJ, 2019; 7: e7728. doi: 10.7717/peerj.7728
Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets 2016; 20 (6): 737–53. doi: 10.1517/14728222.2016.1114102
Imani S, Wu RC, Fu J. MicroRNA-34 family in breast cancer: From research to therapeutic potential. J. Cancer 2018; 9 (20): 3765–75. doi: 10.7150/jca.25576
Tokumaru Y, Katsuta E, Oshi M, et al. High expression of miR-34a associated with less aggressive cancer biology but not with survival in breast cancer. Int J of Mol Sci 2020; 21 (9): 3045. doi: 10.3390/ijms21093045
Kim SY, Kawaguchi T, Yan L, et al. Clinical relevance of microRNA expressions in breast cancer validated using the cancer genome atlas (TCGA). Ann Surg Oncol 2017; 24 (10): 2943–49. doi: 10.1245/s10434-017-5984-2
Alhasan L. MiR-126 modulates angiogenesis in breast cancer by targeting VEGF-A-mRNA. Asian Pac J Cancer Prev 2019; 20 (1): 193. doi: 10.31557/APJCP.2019.20.1.193
Li F. Expression and correlation of miR 124 and miR 126 in breast cancer. Oncol Lett 2019; 17 (6): 5115–9. doi: 10.3892/ol.2019.10184
Rouigari M, Dehbashi M, Tabatabaeian H, et al. Evaluation of the expression level and hormone receptor association of miR-126 in breast cancer. Indian J Clin Biochem 2019; 34 (4): 451–7. doi: 10.1007/s12291-018-0766-6
Thomopoulou K, Papadaki C, Monastirioti A, et al. MicroRNAs regulating tumor immune response in the prediction of the outcome in patients with breast cancer. Front Mol Biosci 2021; 8: 668534. doi: 10.3389/fmolb.2021.668534
Yang H, Yu J, Wang L, et al. miR 320a is an independent prognostic biomarker for invasive breast cancer. Oncol Lett 2014; 8 (3): 1043–50. doi: 10.3892/ol.2014.2298
Yu J, Wang JG, Zhang L, et al. MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin. Oncotarget 2016; 7 (25): 38612. doi: 10.18632/oncotarget.9572
Berber U, Yilmaz I, Narli G, Haholu A, et al. miR-205 and miR-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer. J Breast Cancer 2014; 17 (2): 143–8. doi: 10.4048/jbc.2014.17.2.143
Noh H, Hong S, Dong Z, et al. Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer 2011; 2 (2): 140–50. doi: 10.1177/1947601911408888
Yang C, Tabatabaei SN, Ruan X, Hardy P. The dual regulatory role of MiR-181a in breast cancer. Cell Physiol Biochem 2017; 44 (3): 843–56. doi: 10.1159/000485351
Cataldo A, Piovan C, Plantamura I, et al. MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget 2018; 9 (46): 27920. doi: 10.18632/oncotarget.24723
